Use of fibrinogen/fibrin degradation products and soluble fibrin complexes for differentiating pulmonary embolism from nonthromboembolic lung disease

Simple item page
dc.contributor.authorBynum, Lincoln J.
dc.contributor.authorHalverson, Colleen Crotty
dc.contributor.authorWilson III, James
dc.creator.orcidhttps://orcid.org/0000-0001-6333-1649
dc.date.accessioned2023-03-10T16:22:46Z
dc.date.available2023-03-10T16:22:46Z
dc.date.issued1976
dc.descriptionPermission to deposit the published version was given through direct contact with the publisher. For more information please see the faculty member's entry in Project INDEX -- EDH 7/19/23
dc.description.abstractTo help differentiate pulmonary embolism from other lung diseases, we measured the degradation products of fibrinogen and fibrin and soluble fibrin complexes in normal control subjects and patients with pulmonary embolism, lung cancer, pneumonia, chronic obstructive pulmonary disease, tuberculosis, asthma, and several miscellaneous disorders. A separate group of patients, who were suspected of having pulmonary embolism but had negative pulmonary angiography, were also tested. Many nonthromboembolic lung diseases frequently were associated with positive fibrinogenjfibrin degradation products or soluble fibrin complexes, but those with high positivity rates for one test tended to have low rates for the other test. Both fibrinogen/fibrin degradation products and soluble fibrin complexes were positive in 55 per cent of patients with pulmonary embolism but only in 4 per cent with nonthromboembolic conditions (P < 0.001), in 7 per cent of patients with negative pulmonary angiography (P < 0.001), and in none of the normal subjects (P < 0.001). Both tests were negative in only 3 per cent of patients with pulmonary embolism but in 35 per cent of nonthromboembolic diseases (P < 0.005), 54 per cent of those with negative pulmonary angiography (P < 0.001), and 79 per cent of normal control subjects (P < 0.001). The combination of fibrinogenjfibrin degradation products and soluble fibrin complexes is more valuable than either test alone in the diagnostic separation of thromboembolic from nonthromboembolic pulmonary diseases.en_US
dc.identifier.citationThis is the published version of an article that is available at https://www.atsjournals.org/doi/abs/10.1164/arrd.1976.114.2.285?journalCode=arrd. Recommended citation: Bynum, L. J., Crotty, C., & Wilson III, J. E. (1976). Use of fibrinogen/fibrin degradation products and soluble fibrin complexes for differentiating pulmonary embolism from nonthromboembolic lung disease. American Review of Respiratory Diseases, 114(2), 285–289. This item has been deposited in accordance with publisher copyright and licensing terms and with the author’s permission.en_US
dc.identifier.urihttps://hdl.handle.net/11274/14641
dc.identifier.urihttps://www.atsjournals.org/doi/abs/10.1164/arrd.1976.114.2.285?journalCode=arrd
dc.language.isoen_USen_US
dc.publisherAmerican Thoracic Societyen_US
dc.rightsPermission to deposit this file was given through direct contact with the publisher. For more information please see the faculty member's entry in Project INDEX -- EDH 7/6/23
dc.subjectNegative pulmonary angiographyen_US
dc.subjectSoybean trypsin inhibitoren_US
dc.subjectRadioactive lung scanningen_US
dc.titleUse of fibrinogen/fibrin degradation products and soluble fibrin complexes for differentiating pulmonary embolism from nonthromboembolic lung diseaseen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Halverson-Use of fibrinogenfibrin degradation products.pdf
Size:
445.82 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.68 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Nursing